All News

The three leading justifications for sticker-shocking drug prices in the US.

There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me).

Global price management will lead the fight-back on margins, writes Arnaud Grunwald.

The European Medicines Agency thought it might at last be back on the road to salvation when Guido Rasi swept into town in 2011 and started ordering greater transparency in the agency’s operations.

Vaccine development is on a roll, boosted by biomedical research uncovering new molecular targets for preventives and treatments.

Human behavior may be the most significant variable in the future of cancer care in two sense.

At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,

Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma.

Several legal cases have challenged the Food and Drug Administration’s approach to regulating industry communications about medical products.

Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.

A national publicity campaign recently succeeded in obtaining early access to an experimental treatment for a seriously ill child,

In light of the risks and challenges inherent in the development of oncologics.

It’s hardly news that biopharmaceutical companies today face increasing pressure to innovate, produce, improve efficiency and quality.

Pharm Exec’s Brand of the Year award is itself a brand with staying power - our first recipient was Merck’s Gardasil papillomavirus vaccine.

Europe’s pharma industry association EFPIA has launched its ”Manifesto for an Integrated Life Sciences Strategy in Europe”.

As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again.

Diabetes, it can be said, is one of the unpleasant side-effects of being human.

The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry.

A CCG had denied funding for oocyte preservation for a woman with Crohn’s disease before she had bone marrow transplant and chemotherapy.

In our final Q&A installment previewing next week’s iPharma2014 digital forum.

Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate.

More than half a century ago, way before anyone had dreamt up the notion of digital disruption.

The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK.

The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing.

The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research.

New data maintenance guidelines have sparked a flurry of activity in Europe.

The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE).

Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market.